Memphasys Ltd

MEM

Company Profile

  • Business description

    Memphasys Ltd is an Australian reproductive biotechnology company developing and commercializing novel reproduction and fertility solutions for humans and animals. The products in its development pipeline include a range of devices, media, and in vitro diagnostic solutions. The company is currently focused on the commercialisation of its patented Felix System, a novel bio-separation technology for assisted reproduction, designed to revolutionise sperm separation in assisted reproductive technology (ART) by providing a rapid, gentle, and automated process. The group has only one operating segment, being Reproductive Technologies, the assets and liabilities of which are located in Australia.

  • Contact

    34-36 Richmond Road
    Level 1
    Homebush West
    SydneyNSW2140
    AUS

    T: +61 284157300

    https://www.memphasys.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    30 June 2026

    Employees

    28

Stocks News & Analysis

stocks

OpenAI is going public as the worst value among its peers

Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks

Wide moat healthcare leader remains undervalued

ASX healthcare giant expected to see uptick in demand from emerging markets.
stocks

This US AI winner has been unstoppable. Is it time to sell?

Astonishing results have driven this AI stock into significantly overvalued territory.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,858.8076.70-0.86%
CAC 408,244.290.000.00%
DAX 4024,944.95149.010.60%
Dow JONES (US)51,561.93874.861.73%
FTSE 10010,360.3228.020.27%
HKSE25,014.66238.74-0.95%
NASDAQ26,830.9623.02-0.09%
Nikkei 22566,791.52679.16-1.01%
NZX 50 Index13,161.9760.360.46%
S&P 5007,584.3130.630.41%
S&P/ASX 2008,629.6075.50-0.87%
SSE Composite Index4,059.001.220.03%

Market Movers